Saturday, January 28, 2023
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Medicine & Health

First in-human investigator-initiated clinical trial started for refractory thyroid cancer patients: Novel targeted alpha therapy using astatine

November 29, 2021
in Medicine & Health
0
Share on FacebookShare on Twitter

A research team from the Graduate School of Medicine at Osaka University has started an investigator-initiated clinical trial of sodium astatine ([211At]NaAt) injection for refractory differentiated thyroid cancer patients. The phase I trial evaluates the safety, pharmacokinetics, and efficacy of astatine for use in alpha therapy in patients with refractory differentiated thyroid cancer who responded inadequately to standard of care.

Conceptual image of the targeted alpha therapy using astatine (<sup>211</sup>At)”></p>
<p class=Credit: Osaka University

A research team from the Graduate School of Medicine at Osaka University has started an investigator-initiated clinical trial of sodium astatine ([211At]NaAt) injection for refractory differentiated thyroid cancer patients. The phase I trial evaluates the safety, pharmacokinetics, and efficacy of astatine for use in alpha therapy in patients with refractory differentiated thyroid cancer who responded inadequately to standard of care.

Most thyroid cancers are differentiated cancer and take up iodine like normal thyroid cells. Radioactive iodine (131I) has long been used clinically for patients with differentiated thyroid cancer in isolated hospital rooms dedicated to radionuclide treatment. However, some patients with multiple metastases are refractory to repetitive 131I treatment despite the targeted regions showing sufficient iodine uptake, and medical institutions have difficulty in maintaining dedicated wards due to limited funds and human resources.

In addition, as radioactive iodine (131I) also emits gamma rays which have a long range, patients need to be admitted alone to special hospital rooms to protect others from radiation exposure. With an increasing number of elderly patients who require help by caregivers, there has been a need for treatment that can be safely implemented on an outpatient basis.

Astatine (211At) is a halogen element with similar chemical properties to iodine. Alpha particles emitted from 211At have higher linear energy transfer as compared to beta particles from 131I, exerting a better therapeutic effect by inducing DNA double strand breaks and free radical formation. Since alpha rays are short in distance and do not travel outside the body, alpha-emitting radionuclides have been approved for outpatient cancer treatment.

“We have demonstrated the efficacy and safety of sodium astatine ([211At]NaAt) injection (trial ingredient code: TAH-1005) in preclinical studies and achieved its stable in-hospital production as an investigational drug at Osaka University Hospital,” says Tadashi Watabe, the investigator of the study.

After approval by the hospital’s institutional review board and regulatory authority, TAH-1005 will be administered to humans for the first time in the world. In the clinical trial, therapy is initiated with a low dose, then doses are titrated upwards. The trial period is between Nov. 2021 and Mar. 2024 with a maximum sample size of 16.

“Once astatine injection is approved as a pharmaceutical product, we expect that alpha therapy will be conducted in an outpatient setting. Single outpatient injection will yield a high therapeutic effect with less burden on both patients and medical institutions,” Watabe notes. “Also, astatine can be labeled with various molecules and antibodies and has the potential to be used as a therapeutic agent for various types of cancer in the future.”



Method of Research

Randomized controlled/clinical trial

Subject of Research

People

Tags: AlphaastatinecancerclinicalinhumaninvestigatorinitiatedPatientsrefractorystartedtargetedtherapythyroidtrial
Share26Tweet16Share4ShareSendShare
  • Logo

    New study shows snacking on mixed tree nuts may impact cardiovascular risk factors and increase serotonin

    70 shares
    Share 28 Tweet 18
  • Ignoring Native American data perpetuates misleading white ‘deaths of despair’ narrative, study finds

    66 shares
    Share 26 Tweet 17
  • Mount Sinai researchers awarded $12 million NIH grant to create a center to unravel novel causes of food allergy and atopic dermatitis

    66 shares
    Share 26 Tweet 17
  • Hydrogen peroxide from tea and coffee residue: New pathway to sustainability

    85 shares
    Share 34 Tweet 21
  • Volcano-like rupture could have caused magnetar slowdown

    64 shares
    Share 26 Tweet 16
  • The next generation of global health innovators: Michelson Prize winners announced

    65 shares
    Share 26 Tweet 16
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Hydrogen peroxide from tea and coffee residue: New pathway to sustainability

Null results research now published by major behavioral medicine journal

Regulating immunological memory may help immune system fight disease, MU study finds

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 205 other subscribers

© 2022 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2022 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In